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Abstract
GB virus C/hepatitis G virus (GBV-C) replication in vitro is inefficient and inconsistent. In this study, clinical isolates of GBV-C were
evaluated using peripheral blood mononuclear cell (PBMC) based culture methods. Isolates varied consistently in their ability to persistently
replicate, and yield increased in cells grown without PHA/IL-2 stimulation. The deduced polyprotein sequence of an isolate that replicated
well was determined (GenBank AY196904) and compared to 20 full-length GBV-C sequences. Fourteen of the 16 unique amino acid
polymorphisms identified were in the coding regions for nonstructural proteins associated with interferon resistance and RNA replication.
These data indicate that clinical GBV-C isolates vary in their ability to persist in culture, do not require PHA/IL-2 stimulation, and that
sequence variability in key regulatory regions may affect growth in PBMC cultures. Since GBV-C appears to inhibit HIV replication in a
coinfection model, these studies should facilitate determination of the mechanism of this interaction.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
GB virus type C/hepatitis G virus (GBV-C) infection of
humans is common; approximately 2% of healthy blood
donors, 15% of HCV-positive individuals, and 25% to 40%
of HIV-infected people have GBV-C RNA in their serum
(Alter et al., 1997; Dawson et al., 1996; Feucht et al., 1997;
Gutierrez et al., 1997; Linnen et al., 1996; Tacke et al.,
1997). GBV-C is the most closely related human virus to
hepatitis C virus (HCV), and infection with either GBV-C
or HCV may result in persistent infection and prolonged
viremia. Approximately 25% of HCV infections are spon-
taneously cleared by the host immune system (reviewed in
Hoofnagle, 1997). In contrast, an estimated 50% to 75% of
GBV-C infections are cleared (reviewed in Alter, 1997).
HCV infection frequently results in chronic, progressive
liver disease; however, GBV-C infection has not been con-
vincingly associated with any disease (Alter, 1997; Alter et
al., 1997).
Several studies have found that people coinfected with
GBV-C and human immunodeficiency virus (HIV) appear
to have longer AIDS-free survival than HIV-infected people
without GBV-C (reviewed in George et al., 2002b). In
addition, GBV-C infection in HIV-positive people was as-
sociated with higher baseline CD4 T-cell counts, lower
plasma HIV RNA concentration, and better response to
antiretroviral therapy (Tillmann et al., 2001; Xiang et al.,
2001; Yeo et al., 2000). The survival benefit of GBV-C
infection in HIV-positive people was most consistently
demonstrated in individuals with GBV-C viremia; however,
people with antibodies to the GBV-C envelope glycoprotein
(E2) and who cleared GBV-C RNA also had improved
survival when compared with HIV-infected people without
evidence of prior or active infection with GBV-C (Tillmann
et al., 2001; Yeo et al., 2000).
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The mechanism by which GBV-C infection alters HIV
disease progression is not established. Tillmann et al.,
(2001) reported an inverse correlation between HIV viral
load and GBV-C plasma RNA concentration, suggesting an
antagonistic effect of GBV-C on HIV replication. GBV-C
was shown to replicate in vitro in peripheral blood mono-
nuclear cells (PBMCs) (Fogeda et al., 1999), and a GBV-C
infectious clone replicated in vitro in the CD4 T-cell
subset of cultured PBMCs (Xiang et al., 2000). In vitro
coinfection of PBMCs with GBV-C and HIV demonstrated
diminished HIV replication (Xiang et al., 2001), suggesting
a direct inhibitory effect of GBV-C on HIV replication.
GBV-C infection of PBMCs did not result in altered ex-
pression of the HIV receptors CD4, CCR5, or CXCR4 in the
first 48 h post infection, nor in decreased PBMC viability or
protein syntheses during the first week post infection when
compared to mock-infected controls (Xiang et al., 2001).
Thus, GBV-C did not appear to alter HIV entry or lead to
decreased HIV replication due to cellular toxicity. Further-
more, the amount of inhibition of HIV replication was
similar when the two viruses were added to PBMCs simul-
taneously or when the HIV infection preceded GBV-C
(Xiang et al., 2001). The inhibitory effect of GBV-C infec-
tion was more pronounced when GBV-C infection preceded
HIV, suggesting that GBV-C replication may induce a cel-
lular factor or factors that inhibited HIV replication (Xiang
et al., 2001).
Fogeda et al. (1999) used plasma from a person with
GBV-C viremia to infect human PBMCs. Distinct quasispe-
cies of GBV-C were identified in culture supernatant fluids
following 30 days in culture that differed from the predom-
inant quasispecies present in the plasma used to initiate
infection, suggesting selection of a culture-adapted species
(Fogeda et al., 2000). In this study, we evaluated clinical
isolates of GBV-C to determine if they differed in their
ability to replicate in vitro, and to further characterize
GBV-C replication and persistence in human PBMC cul-
tures. We found considerable variation in the persistence
and amount of GBV-C replication in PBMCs, suggesting
that both viral determinants and donor cell variability were
important in GBV-C replication. In addition, we determined
the nucleotide sequence of the entire coding region of a
clinical GBV-C isolate that replicated for 60 days in
PBMC cultures. We compared the sequence of this isolate
to the sequence of the isolate we used to prepare the GBV-C
infectious clone, which did not replicate in PBMC cultures
beyond 14 days, and to 20 full-length GBV-C sequences in
GenBank.
Results
GBV-C isolates from 12 HIV-positive people who had
GBV-C RNA detected in blood on at least two prior occa-
sions were analyzed in infectivity experiments. These GBV-
C/HIV-coinfected people had a mean CD4 T-cell count of
305 cells/mm3 (range 64–885 cells/mm3), mean CD8 T-
cell count of 1324 cells/mm3 (range 540–2588 cells/mm3),
and mean ALT values of 36 U/L (range 10–147 U/L) (Table
1). Four of the patients had detectable HIV RNA in plasma
at the time of PBMC collection, and 3 patients were HCV
antibody positive. The mean age was 45 years (range 28–60
years); 10 patients were male, 1 patient was African-Amer-
ican, and 11 patients were white (data not shown). Ten
patients reported sexual risk factors for HIV transmission
and 2 reported IV drug use (data not shown). These 12
patients were representative of our clinic population.
Plasma GBV-C quantification and characterization
All 12 patients had GBV-C RNA detected in plasma on
the day of PBMC collection, ranging from 22,950 genome
equivalents (GE)/mL to 5.6  108 GE/ml using real-time
PCR (Table 2). Semiquantitative nested RT-PCR reactions
performed using serial dilutions of patient plasma RNA as
template confirmed the GBV-C RNA concentrations within
an order of magnitude (Table 2). Eleven of 12 patients were
infected exclusively with GBV-C genotype 2; whereas pa-
tient 3 had PCR products using primers specific for both
genotypes 1 and 2. As described by others 3 patients (1, 6,
and 7) had detectable GBV-C E2 antibody in the same
plasma sample used to quantitate RNA and perform infec-
tivity studies (data not shown; Tillmann et al., 2001).
GBV-C infectivity studies
Phytohemaggluttinin (PHA) and interleukin-2 (IL-2)
stimulated PBMCs from GBV-C/HIV-coinfected patients
were cultured with and without supplementation with PB-
MCs obtained from healthy donors (HD), and HD PBMCs
were infected with GBV-C RNA-positive plasma (Fig. 1).
GBV-C RNA was detected in both supernatant and cultured
Table 1
Clinical features of GBV-C/HIV-coinfected patients studied
Patient CD4 cellsa CD8 cellsa HIV RNAb HCV antibodyc ALT
1 251 1086 400 Pos 57
2 161 540 400 Neg 22
3 64 654 233,000 Neg 48
4 127 928 69,000 Pos 147
5 197 1942 400 Neg 19
6 443 1894 400 Neg 23
7 254 1129 400 Neg 16
8 701 1336 400 Neg 19
9 885 2588 400 Pos 30
10 113 1806 20,000 Neg 25
11 222 1126 400 Neg 11
12 247 856 500 Neg 10
a CD4 and CD8 cells  number of cells/mm3.
b HIV RNA  genome equivalents/mm3.
c Pos.  positive; Neg.  negative; ALT  alanine amino transferase,
IU/ml.
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PBMCs from all 12 patients; however, persistence of
GBV-C RNA in culture varied significantly between pa-
tients (Fig. 2A). PBMC cultures from patients 8 through 12
consistently had GBV-C RNA detected in culture superna-
tant and PBMCs for 7 days, while patients 1–6 did not
have GBV-C RNA detected in culture after 7 days. GBV-C
persistence in culture was not enhanced by coculture with
HD PBMCs (Fig. 2B and C). GBV-C RNA detection in
PBMC cell lysates was consistent with culture supernatant
findings (data not shown). The concentration of GBV-C
RNA in GBV-C RNA-positive donor PBMCs and in
healthy donor cells infected with GBV-C isolates was low,
ranging from 1 genome equivalent per 1500 to 200,000
PBMCs (data not shown). Studies are under way to develop
methods to quantify the percentage of PBMCs productively
infected with GBV-C. No difference in cell viability was
noted between different patients’ PBMC cultures or be-
tween PBMCs cultured with and without HD PBMCs with
the exception of patient 3, whose cultured PBMCs were no
longer viable after day 7 (probably due to the high HIV
inoculum; (Table 1). When pooled stimulated HD PBMCs
were infected simultaneously with 20 l of each patient’s
plasma, patients 8 and 10–12 reproducibly had GBV-C
Table 2
Characteristics of GBV-C viremia in 12 patients with GBV-C/HIV
coinfection
Patient Plasma GBV-C titer GBV-C genotype
Real-time PCR Quantitative PCR (Td)
1 2.97  105b 2.5  105 2
2 9.5  105 2.5  105 2
3 2.25  106 2.5  106 1, 2
4 5.86  106 2.5  106 2
5 2.2  104 2.5  104 2
6 9.26  105 2.5  105 2
7 5.65  105 2.5  105 2
8 1.16  108 2.5  108 2
9 5.6  108 2.5  108 2
10 1.19  105 2.5  105 2
11 1.60  106 2.5  105 2
12 4.26  108 2.5  108 2
Note. All data represent GBV-C RNA genome equivalents/ml of plasma
determined in nested RT-PCR reactions. Td  semiquantitative PCR
determined by terminal dilution of input RNA.
Fig. 1. Culture methods used to characterize GBV-C replication. Plasma
and PBMCs were isolated from GBV-C/HIV-infected people by standard
methods and PBMCs were cultured alone (A) or supplemented with an
equal number of healthy donor PBMCs (B). Alternatively, GBV-C-positive
plasma was used to infect healthy donor PBMCs (C). Culture supernatants
and cells were collected for GBV-C RNA analysis.
Fig. 2. GBV-C clinical isolates were analyzed for infectivity using three
modalties. The mean duration of persistence for all experiments is shown,
along with the minimum (solid boxes) and maximum (open boxes) dura-
tion of GBV-C RNA detection in culture supernatants for all three culture
modalities (A). PBMCs were cultured without (B) or with (C) supplemen-
tation with an equal number of donor PBMCs. Insufficient cells were
available for PBMC culture for subject 8. nt  not tested. The GBV-C
plasma RNA titer (GE  105ml plasma) for each patient is shown beneath
the x axis.
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RNA detectable in supernatants for 14 days or longer, con-
sistent with the findings of the PBMC cultures (Fig. 2A).
These infections utilized a single donor pool, were per-
formed in duplicate, and were repeated with consistent re-
sults. PBMCs of all cultures remained viable for 21 days.
Fig. 3 illustrates the relationship between persistent infec-
tion and input GBV-C concentration. Of note, the amount of
input GBV-C RNA did not correlate well with persistent
replication; for example, patient 10 demonstrated persistent
infection despite a plasma GBV-C RNA concentration 60-
fold less than that of patient 4, whose GBV-C did not persist
in culture (Fig. 3). To determine if the GBV-C replication
observed for these 12 isolates in PBMC culture was inde-
pendent of the input GBV-C RNA, plasma obtained from
the 12 GBV-C/HIV-coinfected people was normalized and
used to infect PHA, IL-2-stimulated HD PBMCs from a
single donor in duplicate (MOI  0.01 GBV-C RNA ge-
nome equivalents). GBV-C RNA was not identified in cul-
ture supernatant fluids 14 days post infection for patients 1,
2, 3, 6, and 11 (data not shown), generally consistent with
the nonnormalized infections.
Pooled HD PBMCs were also infected with plasma from
an HIV-negative, GBV-C RNA-positive subject (patient 13;
the source patient used to prepare the infectious clone) and
culture supernatants derived from cells initially transfected
with RNA transcribed from the infectious clone AF121950.
The clinical isolate (patient 13) and virus derived from the
infectious clone (patient 14) replicated for only 14 days
(range 3–14 days; Fig. 4). In contrast, PBMCs from patient
12 demonstrated replication for 60 days.
GBV-C isolates from culture supernatant fluids (20 l of
inocula) were serially passaged 4 times into HD PBMCs.
Culture supernatants from each patient’s last PBMC culture
that tested positive for GBV-C RNA served as the inocula.
PBMC cultures were maintained for 2 weeks, with fresh HD
PBMCs added 7 days post infection. Serial passage of
GBV-C from patients 1, 7, and 11 was not done due to
insufficient culture supernatant material. All 9 patients who
had supernatant available for passage demonstrated replica-
tion in PBMC cultures at the end of four passages, and
GBV-C replication and persistence appeared improved
when compared with initial PBMC cultures (Fig. 5). For
example, patients 5 and 6 had GBV-C RNA in passaged
culture supernatant for 14 days, compared to only 5 days in
the original PBMC culture.
To determine if selection for specific minor quasispecies
in the initial plasma inocula replicated preferentially in
PBMC culture, a 194-bp segment of the NS5A sequence
homologous to the putative interferon-sensitivity determin-
ing region of HCV was amplified from both the initial
plasma sample and from the last GBV-C RNA-positive
coculture supernatant sample from patients 2, 4, 5, and 8. A
minimum of five clones from each sample were sequenced.
The NS5A sequence of patients 2, 4, and 5 was the same in
the plasma-derived GBV-C and in the culture supernatant-
derived GBV-C. In contrast, patient 8 demonstrated selec-
Fig. 3. Correlation between input GBV-C RNA concentration and maxi-
mum time of persistent infection. Plasma GBV-C RNA concentration in 20
l from lowest to highest is presented on the x axis.
Fig. 4. GBV-C persistence of clinical isolates. GBV-C from an HIV-
negative source patient (no. 13) and from virus derived from the GBV-C
infectious clone (no. 14) were used to infect healthy donor PBMCs and
compared with plasma GBV-C from patients 8 and 12. The clone was
prepared from patient 13 (GenBank no. AF121950). **GBV-C from pa-
tient 12 persisted in PBMC cultures for 60 days (data not shown).
Fig. 5. Serial passage of GBV-C from PBMC coculture supernatant into
donor PBMCs. The same donor pool was used for each passage, and all
cultures were maintained for 14 days. Supernatant from patients 1, 7, and
11 were not available for testing. Total days GBV-C RNA was detected in
culture supernatant after four passages is shown for each patient.
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tion of a distinct quasispecies containing 14 mutations in all
5 clones sequenced (Fig. 6). These mutations did not result
in a predicted amino acid change in NS5A; however, the
data are consistent with the selective replication of a minor
quasispecies in PBMC culture, as has been described pre-
viously (Fogeda et al., 2000).
To determine if PHA/IL-2 stimulation of PBMCs was
required for GBV-C replication in PBMC cultures, PBMCs
from patient 12 were cultured with and without IL-2 and
PHA. In addition, serum from patient 12 was used to infect
HD PBMCs, which were then cultured with and without
IL-2 and PHA. GBV-C RNA in culture supernatant from
day 7 was quantified by real-time PCR. Fig. 7 demonstrates
that the amount of GBV-C RNA detected in supernatant
was significantly greater in both serum-infected HD cells
and infected patient PBMCs when IL-2 and PHA were not
added to culture media.
To evaluate HIV replication in the PBMC cultures, HIV
p24 antigen was measured in supernatants obtained from
cocultured patient PBMCs and infected HD PBMCs on day
14. No HIV p24 antigen was detected in supernatants of
infected HD PBMCs; however, HIV p24 antigen was de-
tected in supernatants from PBMC cocultures of patients 4,
6, and 10 (data not shown). Patients 4 and 10 both had
detectable HIV in plasma on the day of PBMC collection
(Table 2).
Sequence analysis of a GBV-C isolate that persists in
PBMC culture
As GBV-C RNA from patient 12 demonstrated persistent
replication in multiple PBMC cultures, we determined the
entire nucleotide (nt) sequence of this isolate. A series of
nested sense and antisense oligonucleotide primers were
designed to span the entire open reading frame (ORF) from
nt 41 to 9349 (sequence numbers based on GBV-C isolate
no. AF121950; GenBank) using a strategy similar to that
previously described (Xiang et al., 2000). PCR products
were purified, ligated into the pTA vector, and the sequence
was determined as described above. At least 5 clones of
each PCR product were sequenced to determine the con-
sensus sequence (GenBank accession no. AY196904).
The sequence contained a long ORF that began at nt 351
Fig. 6. Selection of GBV-C nucleotide mutations in supernatant on day 14 (patient 8). A segment of the NS5A region is shown (panel A  1–97; panel B
 98–194). The nucleotide sequence of the plasma GBV-C isolate is shown (4 clones) and compared to the sequence obtained from day 14 culture
supernatant (5 clones).
Fig. 7. Peripheral blood mononuclear cells (PBMCs) from a GBV-C/HIV-
infected patient (patient 12; G  donor) and healthy donor PBMCs in-
fected with patient serum from patient 12 (G  donor) were cultured with
and without PHA/IL-2 supplementation in media for 14 days. GBV-C
RNA concentrations measured in day 7 culture supernatant are shown. The
results were consistent at day 14.
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(using sequence numbering of AF121950) and extending to
nt 9080. This ORF is predicted to encode a 2974-amino acid
polyprotein with a molecular weight (MW) of 313,788
daltons. If translation initiates upstream of the amino ter-
minus of the predicted E1 protein (Simons et al., 1996), the
polyprotein would be 2906 amino acids (MW 312,989 dal-
tons). There are 4 AUG codons in frame with the polypro-
tein upstream of the putative translational start site of
GBV-C in this isolate, which could potentially encode a
core protein. The complete GBV-C sequence of this isolate
was compared with 20 full-length human isolates obtained
by searching GenBank for complete GBV-C sequences
(GenBank accession nos: AF121950, AB320090, AB320091,
AB320092, AB003293, AB008335, D90600, D90601,
D87255, D87262, D87708, D87709, D87710, D87711,
D87712, D87713, D87714, D87715, U44402, and U63715).
Nucleotide and predicted amino acid sequences were
aligned, and the evolutionary distance between sequences
was determined using the Jukes-Canter method (DNAMAN
software, Lynnon BioSoft Inc., Quebec, Canada). Compar-
ison of the polyprotein sequence of these isolates revealed a
96.53% homology in the polyprotein coding sequences (Fig.
8). Sixteen of these sequences (all except AB320090,
AB320091, AB320092, and AB320093) contained the com-
plete 5ntr and 3ntr sequence, allowing comparison of
full-length genome nucleotide sequences. Comparison of
these isolates revealed 89.54% homology at the nucleotide
level (data not shown).
A consensus predicted amino acid sequence was gener-
ated from these 21 GBV-C polyproteins (initiating transla-
tion at nt 554 of AF121950). There were 62 amino acids
differing between our isolate and the consensus sequence
(2.9%). Based on the predicted protein encoding regions of
the genome, most of the differences between our sequence
and the consensus sequence occurred in the NS2 and E2
coding regions (4.6% and 4.4%, respectively), followed by
the NS5A region (3.6%), NS4 (2.5%), NS5B (2.1%), E1
(1.6%), and NS3 (1.2%). There were 16 amino acid poly-
morphisms identified in our isolate that are not present in
any reported GBV-C sequence. Fourteen of these were in
nonstructural proteins NS5A (6), NS5B (4), and NS3 (4) as
seen in Fig. 9A.
Since AY196904 (patient 12) reproducibly demonstrated
prolonged replication in PBMC cultures, and AF121950
isolate did not, we compared the predicted amino acid
sequence for the polyproteins of these two isolates. There
was 97.6% homology between the two isolates, and the
region of greatest divergence was E1 (5.3%) followed by E2
(3.6%), NS2 (3.2%), NS4 (1.9%), NS5A (1.7%), NS5B
(1.6%), and NS3 (1.3%). Of note, the NS5B substitutions
I 3 V at 2465 and A 3 G at 2795 are very similar to
mutations in HCV NS5B that are associated with increased
RNA replication in HCV RNA replicon systems (Lohmann
et al., 2001; Fig. 9B). Specifically, HCV substitutions
I2442V and R2884G were found to result in a 500-fold
increase in RNA replication (Lohmann et al., 2001). In
addition, the substitutions 2070–2071 VS3 MT and 2074
I 3 L are found in the region homologous to the putative
interferon-sensitivity determining region of HCV (Fujisawa
et al., 2000; Kato et al., 1999), and are not found in any
other GenBank sequence (Fig. 9C). We previously identi-
fied similar substitutions (2069–2071 EVS 3 KMT) in an
interferon-sensitive GBV-C clinical isolate (Xiang J., Mar-
tinez-Smith, C., Gale, M., Jr., Chang, Q., LaBrecque, D.R.,
Schmidt, W.N., Stapleton, J.T., submitted), suggesting that
this region may be important in evasion of natural host
antiviral defense mechanisms. NS5A is thought to be phos-
phorylated in HCV (Reed and Rice, 1999; Reed et al.,
1997). The mutations noted in Fig. 9C would potentially
alter phosphorylation at amino acids 2071 and 2151.
Discussion
GBV-C replication has been associated with decreased
HIV replication in vitro (Xiang et al., 2001) and in vivo
(Tillmann et al., 2001; Xiang et al., 2001). In our experi-
ence, GBV-C in vitro replication methods were inefficient
and inadequately reproducible, even using an infectious
molecular clone. To better characterize GBV-C replication,
we employed three different PBMC-based culture methods
to measure persistence of GBV-C replication in culture.
Fig. 8. Comparison of the predicted full-length polyprotein sequence of the
isolate from patient 12 (GenBank no. AY196904) with predicted polypro-
tein sequences of 20 full-length GBV-C RNA sequences. The phylogenetic
tree was created using the Jukes-Cantor method and percentage homolo-
gies of the polyprotein sequences are shown. Isolates AY196904 (patient
12) and AF121950 (infectious clone) are highlighted, as these are the only
isolates characterized for replication in PBMC culture.
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Fig. 9. Amino acid polymorphisms in AY196904. Sixteen amino acids were identified in AY196904 that were not present in the other sequences (A).
Comparing the isolate from patient 12 (AY196904) with the infectious clone (AF121950), 2 amino acid differences were identified in the NS5B region (panel
B) similar to those related to RNA replication in HCV (Lohmann et al., 2001). Similarly, comparison of predicted NS5A amino acid sequences from
AY196904 and AF121950 revealed differences in a region homologous to the HCV interferon-sensitivity determining region (C).
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Clinical isolates propagated either from GBV-C-infected
patient PBMCs or donor PBMCs infected with GBV-C
RNA-positive plasma demonstrated two growth patterns.
Seven of the 12 clinical isolates demonstrated GBV-C
growth in culture supernatants for 7 days, while 5 isolates
consistently persisted in culture for 14 days (Fig. 2). With
two exceptions (patients 4 and 11), the growth pattern was
consistent when cultures were normalized for input GBV-C
RNA. Coculture of GBV-C-positive PBMCs with donor
PBMCs did not improve GBV-C persistence, and GBV-C
culture in media supplemented with PHA and IL-2 inhibited
growth (Fig. 7). Since the 12 GBV-C isolates persisted for
similar duration in PBMC cultures from either pooled or
single donors on multiple occasions, it appears that the
capacity to persist in PBMC cultures is an intrinsic viral
characteristic. Nevertheless, host-cell factors may also con-
tribute to this persistence.
Replication of GBV-C in these three culture systems was
not associated with cell toxicity, as significant cell death
was noted in only one patient’s PBMC cultures. GBV-C
replication was independent of the source patient’s CD4
T-cell count, CD8 T-cell count, hepatitis C antibody sta-
tus, gender, age, or HIV acquisition mode. High HIV RNA
levels detected in patients 3 and 4 may explain the relatively
poor GBV-C replication of these isolates. However, when
GBV-C from patient 3 was tested for growth in HD PBMCs
at a time with the source patient’s HIV RNA was 400, no
improvement in GBV-C growth was noted, and GBV-C
from patient 10 consistently grew well in culture despite
ongoing detectable HIV RNA (data not shown).
GBV-C replication in PBMC culture did not correlate
with plasma GBV-C RNA titer (Fig. 3), and growth patterns
remained distinctive when GBV-C RNA input was normal-
ized. The 12 patients studied had a broad range of GBV-C
RNA concentrations, ranging from 2.2  104 to 5.6  108
GE/ml. These data indicate that the range of GBV-C RNA
concentrations in patient plasma varies more widely than
either HIV or HCV (Tillmann et al., 2001). The relationship
between GBV-C RNA concentration and HIV replication
requires further study.
Serial passage of culture supernatant fluids into donor
PBMCs appeared to result in prolongation of GBV-C rep-
lication in PBMCs (Fig. 5). Improved replication of GBV-C
passaged from culture supernatant fluids into donor PBMCs
may represent selection of viral quasispecies more adapted
for in vitro replication. Consistent with this, we isolated a
distinct GBV-C quasispecies in culture supernatants from
patient 8 that was not identified in patient plasma prior to
culture (Fig. 6), as noted by others (Fogeda et al., 2000).
Studies are under way to further adapt GBV-C to growth in
cell culture systems.
In the course of these studies, we noted that GBV-C from
patient 12 consistently demonstrated prolonged replication
in culture. This isolate persisted in PBMC culture longer
than GBV-C from an HIV-negative patient, and when com-
pared with our previously described infectious clone. The
full-length sequence of the polyprotein coding region of this
isolate (AY196904) revealed 97.6% homology with the
predicted polyprotein consensus sequences of 20 other full-
length GBV-C genomes in GenBank. Sixteen unique amino
acid substitutions were found, clustered in the key replica-
tion nonstructural proteins NS3, NS5A, and NS5B (Fig.
9A). This GBV-C isolate contained amino acid substitutions
in both NS5A and NS5B coding regions similar to changes
identified in HCV NS5A and NS5B previously found to be
involved in interferon sensitivity and enhanced RNA repli-
cation (Blight et al., 2000; Gale et al., 1998; Krieger et al.,
2001). Thus, amino acid substitutions in key GBV-C pro-
teins may play critical roles in viral replication and host
immune evasion. We are constructing chimeric virsuses
using AF121950 and AY196904 sequences to further ex-
plore this possibility.
In summary, GBV-C in the plasma of individuals with
HIV coinfection demonstrated different replication pheno-
types in PBMC-based cultures in vitro. No improvement in
GBV-C replication was noted when cultures were supple-
mented with donor PBMCs, and GBV-C replication was
decreased when IL-2 and PHA were added to PBMC cul-
tures. Persistence of GBV-C replication in PBMCs was not
correlated with clinical features of the source patient, in-
cluding plasma GBV-C RNA concentration or the presence
of E2 antibody. Specific nucleotide sequence mutations
were identified following 2 weeks in culture in one isolate,
suggesting that specific GBV-C nucleotide polymorphisms
may influence GBV-C in vitro replication. The full-length
polyprotein sequence of a GBV-C isolate that consistently
demonstrated prolonged replication in culture also con-
tained unique amino acid substitutions in nonstructural pro-
teins involved in viral replication and evasion of the host
immune response. Given the in vivo and in vitro evidence
that GBV-C replication is associated with inhibition of HIV
replication, it is hoped that these studies may allow the




Individuals attending the University of Iowa HIV clinic
between 1999 and 2002 were invited to participate in a
study of GBV-C infection. In addition, an HIV-negative,
GBV-C RNA-positive person and several healthy individ-
uals (who were negative for HIV, HCV, and GBV-C) par-
ticipated in these studies. Informed consent was obtained
from all participants and the study was approved by the
University of Iowa Institutional Review Board. Medical
records were reviewed to confirm HIV results and related
clinical information. HIV-RNA and CD4 T-cell counts
were obtained within 30 days of blood collection for these
studies, and ALT levels were obtained within 90 days. HCV
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antibody testing was performed during the initial clinic
visit. All statistics were performed using SigmaStat soft-
ware V2.03S (Jandel Scientific, Chicago, IL).
GBV-C RNA detection and sequence determination
Blood samples were anticoagulated (acid-citrate-dex-
trose; Becton-Dickinson, Franklin Lakes, NJ) and processed
within 2 h of collection. Whole blood or plasma (200 l)
was added to 500 l of GITC solution and stored at 80°C
as previously described (Schmidt et al., 1995; Xiang et al.,
1998). RNA was extracted as previously described (George
et al., 2002a), and the final RNA quantity used as template
in each RT-PCR reaction represented 50 l of the original
sample. Primers from the GBV-C 5 nontranslated region
(5ntr) of GBV-C (nt nos. 23–330) were used in nested
RT-PCR reactions as previously described (Schmidt et al.,
1997, 1997a, 1997b; Stapleton et al., 1999; Xiang et al.,
1998). In addition, primers from the GBV-C NS5A region
(nt nos. 6651–6877) were used to amplify viral RNA (outer
antisense: TACTGCARTCYTCCATGATGACAT; outer
sense: ATGGTYTAYGGYCCTGGVCAAA; nest anti-
sense: TTCAAGAATCCTCGCAGCATTCT; nest sense:
CTGGVCAAAGYGTYACCATT). All sequence numbers
are based on the sequence of the infectious GBV-C clone,
GenBank accession no. AF121950 (Xiang et al., 2000). At
least 2 negative and positive control samples were evaluated
with each PCR reaction, and all samples and controls were
tested in duplicate. Where noted, RNA extracted from cul-
ture supernatant fluids (50 l) and PBMCs (5  105) was
tested for GBV-C RNA in nested RT-PCR reactions as
previously described (George et al., 2002a; Xiang et al.,
2000). To determine GBV-C genotype, first round products
from 5ntr RT-PCR were amplified using primers specific
for GBV-C genotypes I–IV as described by Naito and Abe,
(2001). PCR products were separated by agarose gel elec-
trophoresis and visualized by ethidium bromide staining.
GBV-C PCR products were purified (Wizard PCR puri-
fication kit; Promega, Madison, WI) and ligated into the
pTA vector (Original TA cloning kit; Invitrogen, Carlsbad,
CA) as previously described (Stapleton et al., 1999). Plas-
mid DNA was sequenced using an ABI automatic sequencer
(University of Iowa DNA Core facility; George et al.,
2002a). Sequences were analyzed using DNAMAN soft-
ware (DNAMAN software; Lynnon BioSoft Inc., Quebec,
Canada).
Culture methods and infectivity assays
PBMCs from GBV-C/HIV-coinfected people and
healthy donors (HD PBMCs) who were HIV, HCV, GBV-C
negative were prepared by Ficoll-Hypaque followed by cen-
trifugation as previously described (Cook et al., 1997).
PBMCs obtained from GBV-C-infected donors were main-
tained in stimulation media (RPMI 1640 media supple-
mented with 10% FCS, 5% recombinant human IL-2;
(Cellular Products Inc., Buffalo, NY), 10 g/ml phytohe-
magglutinin (PHA; Difco, Detroit, MI), and 10 g/ml lipo-
polysaccharide (Escherichia coli LPS; Sigma) at a concen-
tration of 2  106 PBMCs/ml for 48 h (Xiang et al., 2000).
PBMCs were then incubated in RPMI 1640 media supple-
mented with 10% FCS, 5% recombinant human IL-2, and 5
g/ml PHA at a concentration of 2  106 PBMCs/ml, and
media were changed weekly. For coculture experiments, an
equal number of PHA/IL-2-stimulated HD PBMCs were
added when PBMCs from GBV-C-infected donors were
obtained and weekly thereafter. For infectivity experiments,
HD PBMCs were stimulated for 48 h prior to infection with
GBV-C or mock serum, and maintained as above.
GBV-C replication and persistence were studied in three
ways (Fig. 1). First, PBMCs from GBV-C/HIV-coinfected
people were cultured without donor cells. Second, PBMCs
from the same people were cultured with the addition of an
equal number of HD PBMCs and fresh HD PBMCs were
added weekly. The same PBMC donor pool was used for
each culture and each weekly supplementation. Finally,
plasma from the same GBV-C RNA/HIV-coinfected people
was used to infect PHA, IL-2-stimulated donor PBMCs.
The same PBMC donor pool was used for each infection,
and plasma infections of all 12 clinical isolates were done
simultaneously. PBMCs (5  105) were removed weekly
and stored in GITC at 80°C until use, and culture super-
natants (500 l) were removed twice weekly and stored at
80°C. Mock control infections of donor PBMCs were
maintained under identical conditions.
GBV-C RNA quantitation
GBV-C RNA was purified from plasma, PBMCs, or
culture supernatant and quantified using both real-time PCR
(Perkin-Elmer, Branchburg, NJ) and endpoint dilution using
nested RT-PCR. RNA from 100 l of plasma was used as
the template for RT-PCR using primers from the 5ntr
region described above. The product of the RT-PCR was
used as the template for real-time PCR with primers
from the 5ntr region (sense primer at nt 211: TACCGGT-
GTGAATAAGGGCC; antisense primer at nt 283:
CGTCGTTTGCCCAGGTG), a 6-FAM/TAMRA-labeled
probe corresponding to nt 241–265 (CTCGTCGTTAAAC-
CGAGCCCGTCAC), and TaqMan Universal PCR Master
Mix (Perkin-Elmer). Samples were incubated at 50°C for 2
min, followed by 95°C for 10 min, then amplified in 40
cycles (50°C for 15 s and 60°C for 1 min) in an ABI Prism
7700 sequence detector. Duplicate positive and negative
controls were performed with each reaction. A standard
curve was determined using terminal dilution PCR to relate
cycle threshholds (Ct) and genome equivalents (GE) of
GBV-C RNA per milliliter of plasma or supernatant (ad-
justed R2  0.985; P  0.001; SigmaStat). Real-time PCR
results were compared with terminal dilution experiments
using RT-PCR. Terminal dilution experiments utilized log10
serial dilutions of RNA as the template for RT-PCR, and
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PCR was performed using primers from two regions of the
genome (5ntr and NS5A).
HIV p24 antigen assay
Culture supernatants fluids obtained 2 weeks post infec-
tion (450 l) were analyzed in duplicate for HIV replication
using Retro-Tek HIV-1 p24 antigen ELISA kits (Zeptome-
trix, Buffalo, NY) as previously described (Wuenschmann
and Stapleton, 2000; Xiang et al., 2001). Duplicate positive,
negative, and substrate controls were run with each assay
and a p24 antigen standard curve from 0 to 125.0 pg/ml was
prepared in accordance with the manufacturer’s instruc-
tions.
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